Home » Stocks » CYT

Cyteir Therapeutics, Inc. (CYT)

Stock Price: $17.98 USD 0.66 (3.81%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $17.50 -0.48 (-2.67%) Jun 22, 6:28 PM
Market Cap 619.65M
Revenue (ttm) n/a
Net Income (ttm) -22.21M
Shares Out 34.46M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $17.98
Previous Close $17.32
Change ($) 0.66
Change (%) 3.81%
Day's Open 17.14
Day's Range 16.71 - 18.33
Day's Volume 170,363
52-Week Range 16.00 - 18.78

News

Hide News

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

12 hours ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, to...

5 days ago - Business Wire

Cyteir Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

About CYT

Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, is in a phase 1... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Jun 18, 2021
CEO
Markus Renschler, M.D.
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
CYT
Full Company Profile

Financial Performance

Financial Statements